Herein, to explore the potential of TYR as a catalyst to activate anti-cancer prodrugs against melanoma drug resistance, we designed a clickable prodrug approach in which drugs will be only toxic against melanoma cells after TYR catalysis. This evidence concerns the gene TYR and cancer.